203 related articles for article (PubMed ID: 33149585)
1. Efficacy of Combination Therapy with Linalool and Doxorubicin Encapsulated by Liposomes as a Two-in-One Hybrid Carrier System for Epithelial Ovarian Carcinoma.
Wi TI; Won JE; Lee CM; Lee JW; Kang TH; Shin BC; Han HD; Park YM
Int J Nanomedicine; 2020; 15():8427-8436. PubMed ID: 33149585
[TBL] [Abstract][Full Text] [Related]
2. Tuftsin-Bearing Liposomes Co-Encapsulated with Doxorubicin and Curcumin Efficiently Inhibit EAC Tumor Growth in Mice.
Murugesan K; Srinivasan P; Mahadeva R; Gupta CM; Haq W
Int J Nanomedicine; 2020; 15():10547-10559. PubMed ID: 33414637
[TBL] [Abstract][Full Text] [Related]
3. Dual-effect liposomes encapsulated with doxorubicin and chlorin e6 augment the therapeutic effect of tumor treatment.
Peng PC; Hong RL; Tsai YJ; Li PT; Tsai T; Chen CT
Lasers Surg Med; 2015 Jan; 47(1):77-87. PubMed ID: 25559348
[TBL] [Abstract][Full Text] [Related]
4. D-α-tocopherol polyethylene glycol 1000 succinate-modified liposomes with an siRNA corona confer enhanced cellular uptake and targeted delivery of doxorubicin via tumor priming.
Tan X; Fang Y; Ren Y; Li Y; Wu P; Yang X; Liu W
Int J Nanomedicine; 2019; 14():1255-1268. PubMed ID: 30863058
[TBL] [Abstract][Full Text] [Related]
5. Cell-penetrating corosolic acid liposome as a functional carrier for delivering chemotherapeutic drugs.
Li X; Widjaya AS; Liu J; Liu X; Long Z; Jiang Y
Acta Biomater; 2020 Apr; 106():301-313. PubMed ID: 32081779
[TBL] [Abstract][Full Text] [Related]
6. Aptamer-drug conjugate: targeted delivery of doxorubicin in a HER3 aptamer-functionalized liposomal delivery system reduces cardiotoxicity.
Dou XQ; Wang H; Zhang J; Wang F; Xu GL; Xu CC; Xu HH; Xiang SS; Fu J; Song HF
Int J Nanomedicine; 2018; 13():763-776. PubMed ID: 29440899
[TBL] [Abstract][Full Text] [Related]
7. A comparative study of polydopamine modified and conventional chemical synthesis method in doxorubicin liposomes form the aspect of tumor targeted therapy.
Bi D; Zhao L; Li H; Guo Y; Wang X; Han M
Int J Pharm; 2019 Mar; 559():76-85. PubMed ID: 30677481
[TBL] [Abstract][Full Text] [Related]
8. Linalool-Incorporated Nanoparticles as a Novel Anticancer Agent for Epithelial Ovarian Carcinoma.
Han HD; Cho YJ; Cho SK; Byeon Y; Jeon HN; Kim HS; Kim BG; Bae DS; Lopez-Berestein G; Sood AK; Shin BC; Park YM; Lee JW
Mol Cancer Ther; 2016 Apr; 15(4):618-27. PubMed ID: 26861249
[TBL] [Abstract][Full Text] [Related]
9. A novel cancer targeting approach based on estrone anchored stealth liposome for site-specific breast cancer therapy.
Paliwal SR; Paliwal R; Mishra N; Mehta A; Vyas SP
Curr Cancer Drug Targets; 2010 May; 10(3):343-53. PubMed ID: 20370682
[TBL] [Abstract][Full Text] [Related]
10. Self-assembly of porphyrin-grafted lipid into nanoparticles encapsulating doxorubicin for synergistic chemo-photodynamic therapy and fluorescence imaging.
Hameed S; Bhattarai P; Liang X; Zhang N; Xu Y; Chen M; Dai Z
Theranostics; 2018; 8(19):5501-5518. PubMed ID: 30555560
[TBL] [Abstract][Full Text] [Related]
11. A comparative study of folate receptor-targeted doxorubicin delivery systems: dosing regimens and therapeutic index.
Scomparin A; Salmaso S; Eldar-Boock A; Ben-Shushan D; Ferber S; Tiram G; Shmeeda H; Landa-Rouben N; Leor J; Caliceti P; Gabizon A; Satchi-Fainaro R
J Control Release; 2015 Jun; 208():106-20. PubMed ID: 25869964
[TBL] [Abstract][Full Text] [Related]
12. Phytosterol-loaded CD44 receptor-targeted PEGylated nano-hybrid phyto-liposomes for synergistic chemotherapy.
Gautam M; Thapa RK; Gupta B; Soe ZC; Ou W; Poudel K; Jin SG; Choi HG; Yong CS; Kim JO
Expert Opin Drug Deliv; 2020 Mar; 17(3):423-434. PubMed ID: 32028805
[No Abstract] [Full Text] [Related]
13. The impact of phospholipids with high transition temperature to enhance redox-sensitive liposomal doxorubicin efficacy in colon carcinoma model.
Mirhadi E; Askarizadeh A; Farhoudi L; Mashreghi M; Behboodifar S; Alavizadeh SH; Arabi L; Jaafari MR
Chem Phys Lipids; 2024 Jul; 261():105396. PubMed ID: 38621603
[TBL] [Abstract][Full Text] [Related]
14. GE11-Directed Functional Polymersomal Doxorubicin as an Advanced Alternative to Clinical Liposomal Formulation for Ovarian Cancer Treatment.
Zou Y; Xia Y; Meng F; Zhang J; Zhong Z
Mol Pharm; 2018 Sep; 15(9):3664-3671. PubMed ID: 29570299
[TBL] [Abstract][Full Text] [Related]
15. MiR-101 and doxorubicin codelivered by liposomes suppressing malignant properties of hepatocellular carcinoma.
Xu F; Liao JZ; Xiang GY; Zhao PX; Ye F; Zhao Q; He XX
Cancer Med; 2017 Mar; 6(3):651-661. PubMed ID: 28135055
[TBL] [Abstract][Full Text] [Related]
16. Lipoic acid-derived cross-linked liposomes for reduction-responsive delivery of anticancer drug.
Ling L; Ismail M; Du Y; Yao C; Li X
Int J Pharm; 2019 Apr; 560():246-260. PubMed ID: 30769133
[TBL] [Abstract][Full Text] [Related]
17. Doxorubicin-loaded nanocarriers: A comparative study of liposome and nanostructured lipid carrier as alternatives for cancer therapy.
Fernandes RS; Silva JO; Monteiro LOF; Leite EA; Cassali GD; Rubello D; Cardoso VN; Ferreira LAM; Oliveira MC; de Barros ALB
Biomed Pharmacother; 2016 Dec; 84():252-257. PubMed ID: 27664949
[TBL] [Abstract][Full Text] [Related]
18. Development of a bone-targeted pH-sensitive liposomal formulation containing doxorubicin: physicochemical characterization, cytotoxicity, and biodistribution evaluation in a mouse model of bone metastasis.
Ferreira Ddos S; Faria SD; Lopes SC; Teixeira CS; Malachias A; Magalhães-Paniago R; de Souza Filho JD; Oliveira BL; Guimarães AR; Caravan P; Ferreira LA; Alves RJ; Oliveira MC
Int J Nanomedicine; 2016; 11():3737-51. PubMed ID: 27563241
[TBL] [Abstract][Full Text] [Related]
19. Anti-tumor effect via passive anti-angiogenesis of PEGylated liposomes encapsulating doxorubicin in drug resistant tumors.
Kibria G; Hatakeyama H; Sato Y; Harashima H
Int J Pharm; 2016 Jul; 509(1-2):178-187. PubMed ID: 27234700
[TBL] [Abstract][Full Text] [Related]
20. Selenium-functionalized liposomes for systemic delivery of doxorubicin with enhanced pharmacokinetics and anticancer effect.
Xie Q; Deng W; Yuan X; Wang H; Ma Z; Wu B; Zhang X
Eur J Pharm Biopharm; 2018 Jan; 122():87-95. PubMed ID: 29032193
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
